Moreover, MSI-1436 is currently under evaluation in Phase 1 and 1b clinical trials for the treatment of obesity and type-2 diabetes [NCT00606112, 2008; NCT00806338, 2009], HER-2 positive metastatic breast cancer [NCT02524951, 2018], as well as atherosclerosis and inflammation [NCT04235023, 2020]. Here, ERBB2 is linked to type 2 diabetes mellitus.